Game-changing ovarian cancer drug which extends survival by three years gets NHS green light

Professor Jonathan Ledermann (UCL Cancer Institute), said: "While survival rates for advanced ovarian cancer are low, our goal when treating women who are newly-diagnosed is long-term remission or even cure."

Read: The Telegraph